Oncology (all articles) | Links Medicus Content Curation & Alerts in Medicine

This phase 3 clinical trial demonstrated interferon alfa + temozolomide prolonged survival time in patients with newly diagnosed high-grade gliomas by median 8 months (18% vs 9% 5yr overall survival), especially with MGMT promoter unmethylated tumors. https://t.co/2yOssnF97G

— JAMA Network Open (@JAMANetworkOpen) January 27, 2023

Cohort Study | Risk of malignant neoplasms of the gastrointestinal tract after blood or marrow transplant

30 Jan, 2023 | 00:23h | UTC

Malignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant – JAMA Oncology (link to abstract – $ for full-text)

Commentary: Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation – The ASCO Post

Commentary on Twitter

Exposure to cytarabine, etoposide and anthracyclines & chronic graft vs. host disease increase risk of colorectal, liver & esophageal cancer after BMT, providing evidence for appropriate evaluation & management in high-risk populations. https://t.co/UENFM1UWRw

— JAMA Oncology (@JAMAOnc) January 23, 2023

Salivary gland cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

27 Jan, 2023 | 12:16h | UTC

Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up – ESMO Open

M-A | Sensitivity and complications of thoracentesis and thoracoscopy for the diagnosis of malignant pleural effusions

27 Jan, 2023 | 12:11h | UTC

Sensitivity and complications of thoracentesis and thoracoscopy: a meta-analysis – European Respiratory Review

Diagnostic Study | Usefulness of CT radiomics in differentiating histologic subtypes of epithelial ovarian carcinoma

27 Jan, 2023 | 12:01h | UTC

Computed Tomographic Radiomics in Differentiating Histologic Subtypes of Epithelial Ovarian Carcinoma – JAMA Network Open

Commentary on Twitter

Radiomic features extracted from contrast-enhanced CT scans were useful in the classification of histologic subtypes in epithelial ovarian carcinoma, high-grade serous carcinoma (HGSC) and non-HGSC. https://t.co/DBAXnl9r0X #OAResearch

— JAMA Network Open (@JAMANetworkOpen) December 6, 2022

M-A | Proximal gastrectomy with double-tract-reconstruction vs. total gastrectomy in gastric and gastroesophageal junction cancer patients

27 Jan, 2023 | 11:54h | UTC

Systematic review and meta-analysis comparing proximal gastrectomy with double-tract-reconstruction and total gastrectomy in gastric and gastroesophageal junction cancer patients: Still no sufficient evidence for clinical decision-making – Surgery

Pre-existing autoimmune disease increases the risk of cardiovascular and noncardiovascular events after immunotherapy

26 Jan, 2023 | 12:09h | UTC

Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy – JACC: CardioOncology

Commentary: Preexisting Autoimmune Disease and Risk for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy for Cancer – The ASCO Post

Review | Lung cancer screening: new evidence, updated guidance

26 Jan, 2023 | 12:08h | UTC

Lung cancer screening: New evidence, updated guidance – Journal of Family Practice

Perspective | Endocrine treatment for 5 years or radiation for 5 days for patients with early breast cancer older than 65 years

26 Jan, 2023 | 12:04h | UTC

Endocrine Treatment for 5 Years or Radiation for 5 Days for Patients With Early Breast Cancer Older Than 65 Years: Can We Do It Right? – Journal of Clinical Oncology

Commentary from the author on Twitter

🚨Hot off the press @JCO_ASCO: For decades we have been offering RT omission for early #bcsm patients, here we discuss how tides have changed and its time to omit hormonal therapy and treat with RT instead @TaghianAlphonse @MGHBreastOnc @LurieCancer

https://t.co/bqoeC1weYS

— George E. Naoum, MD, MMSCI (@George_E_Naoum) December 20, 2022

RCT | Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion

26 Jan, 2023 | 12:03h | UTC

Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study – Journal of Clinical Oncology

RCT | Preoperative chemotherapy reduced recurrence in operable colon cancer

25 Jan, 2023 | 11:29h | UTC

Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial – Journal of Clinical Oncology

Editorial: FOxTROT: Are We Ready to Dance? – Journal of Clinical Oncology

News Release: Chemotherapy before surgery cuts risk of colon cancer returning, trial finds – Cancer Research UK

Commentary: New treatment strategy cuts risk of bowel cancer returning by 28% – The Guardian

Commentary from one of the authors on Twitter (thread – click for more)

🥁🥁🥁Tweetorial
FOxTROT, the 1st ph 3 RCT of neoadjuvant chemo (NAC) in locally advanced colon cancer
We report that NAC is
✅deliverable and safe
✅led to statistically significant reduction in cancer recurrence than upfront surgery
A 🧵 (1/14)#crcsm https://t.co/y1hU6qWdXF

— Jenny Seligmann (@JenSeligmann) January 20, 2023

Consensus Paper | Tumor surveillance guidelines for individuals with neurofibromatosis type 1

25 Jan, 2023 | 11:24h | UTC

ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1 – eClinicalMedicine

Single-arm phase 2 study | Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors

24 Jan, 2023 | 14:19h | UTC

Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors – Journal of Clinical Oncology (link to abstract – $ for full-text)

Editorial: Immunotherapy in Localized Microsatellite Instability–High/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care? – Journal of Clinical Oncology

Commentary: Neoadjuvant Pembrolizumab in Localized MSI-H/dMMR Solid Tumors – The ASCO Post

RCT | Breast-cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection vs. standard surgical treatment of axilla

24 Jan, 2023 | 14:15h | UTC

Occurrence of breast-cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two-arm randomized clinical trial – Cancer

Commentary on Twitter

New & available #OpenAccess | Occurrence of breast-cancer–related #lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two-arm randomized clinical trial https://t.co/fXB7PfysCH @OncoAlert pic.twitter.com/wWNhC9BMvY

— ACS Journal Cancer (@JournalCancer) October 20, 2022

Meta-analysis reaffirms benefits of O-RADS MRI for diagnosing indeterminate adnexal lesions

24 Jan, 2023 | 14:05h | UTC

Commentary: Meta-Analysis Reaffirms Benefits of O-RADS MRI for Diagnosing Indeterminate Adnexal Lesions – Diagnostic Imaging

Original Study: O-RADS MRI: A Systematic Review and Meta-Analysis of Diagnostic Performance and Category-wise Malignancy Rates – Radiology (link to abstract – $ for full-text)

Commentary on Twitter

A meta-analysis of 4520 adnexal lesions from 12 studies showed that MRI O-RADS has a 92% summary sensitivity and a 91% summary specificity in characterizing lesions that are indeterminate at US. https://t.co/WSJVQUiM4T pic.twitter.com/kssAK2s02N

— Radiology (@radiology_rsna) November 23, 2022

Stay Updated in Your Specialty